Bio-Techne Corp Congressional Trading
According to U.S. congressional financial disclosures filed under the STOCK Act, members of Congress have reported 73 trades in Bio-Techne Corp (NASDAQ: TECH) since 2014, across 13 members, worth an estimated $1.7M in disclosed volume (the midpoint of the dollar ranges members report, not exact amounts). 33 buys against 40 sells, a modestly sell-led skew, with Democratic members responsible for 77% of the trades and Republican members 23%. The most recent disclosure shown was filed July 2026, and April McClain Delaney has filed the most TECH transactions among those shown, with 8. Other recent filers include Rohit Khanna. One notable disclosed move was a purchase by Rohit Khanna on May 15, 2026, up 64.8% since. These figures are drawn from public House and Senate periodic transaction reports and reflect what members were required to disclose, not the current market value of any position. For the full record, including the month-by-month buy and sell timeline, the party breakdown, top buyers and sellers, and every individual filing, see the Bio-Techne Corp (TECH) stock overview and the complete trade table below.
Data updated
Price & congressional trade timeline
Party breakdown
Bio-Techne congressional trading activity
| Politician | Published | Traded | Filed After | Type | Size | Return | Owner | |
|---|---|---|---|---|---|---|---|---|
 Rohit Khanna House | Jul 6, 2026 | Jun 30, 2026 | 6 days | SELL |  $1,001 - $15,000 | +0.82% | Spouse | |
Rohit Khanna House | Jul 6, 2026 | Jun 2, 2026 | 34 days | SELL | $1,001 - $15,000 | +43.12% | Dependent Child | |
Rohit Khanna House | Jun 9, 2026 | May 15, 2026 | 25 days | BUY | $1,001 - $15,000 | +64.81% | Spouse | |
Rohit Khanna House | May 11, 2026 | Apr 13, 2026 | 28 days | SELL | $1,001 - $15,000 | +24.04% | Spouse | |
| May 6, 2026 | Apr 8, 2026 | 28 days | SELL | $1,001 - $15,000 | +29.26% | Dependent Child | ||
Rohit Khanna House | Apr 7, 2026 | Mar 30, 2026 | 8 days | BUY | $1,001 - $15,000 | +37.13% | Dependent Child | |
| Apr 6, 2026 | Mar 26, 2026 | 11 days | SELL | $1,001 - $15,000 | +35.41% | Dependent Child | ||
| Mar 10, 2026 | Feb 24, 2026 | 14 days | SELL | $1,001 - $15,000 | +23.89% | Dependent Child | ||
Rohit Khanna House | Feb 6, 2026 | Jan 29, 2026 | 8 days | BUY | $1,001 - $15,000 | +11.69% | Spouse | |
| Feb 2, 2026 | Jan 28, 2026 | 5 days | SELL | $1,001 - $15,000 | +9.00% | Dependent Child |
Bio-Techne (TECH) congressional trading FAQ
Can members of Congress legally trade Bio-Techne (TECH) stock?
Yes. Members of Congress are permitted to trade individual stocks, including Bio-Techne (TECH), but the STOCK Act of 2012 requires them to publicly disclose each transaction within 45 days. Quantellect tracks those disclosures; it does not imply any trade was improper.
Are congressional Bio-Techne (TECH) trades public?
Yes. Every congressional trade in Bio-Techne (TECH) on this page comes from mandatory public STOCK Act disclosure filings, which are filed with a delay and may be revised.
How many times has Congress traded Bio-Techne (TECH)?
Members of Congress have disclosed 73 trades in Bio-Techne (TECH) worth $1.7M across 13 members, according to public STOCK Act filings.
Which members of Congress have traded Bio-Techne (TECH)?
Recent and active filers of Bio-Techne (TECH) disclosures include April McClain Delaney, Rohit Khanna. The full member-by-member trade list is on this page.
Do Democrats or Republicans trade Bio-Techne (TECH) more?
Across disclosed Bio-Techne (TECH) trades, 77% were by Democrats and 23% by Republicans, led by Democrats (77%).
What is the most recent congressional Bio-Techne (TECH) trade?
The most recent disclosed Bio-Techne (TECH) trade was a sale by Rohit Khanna, filed Jul 5, 2026.
Browse all stocks Congress tradesCongressional trading overviewBio-Techne (TECH) stock overview
Not investment advice. Congressional trading data is sourced from public STOCK Act disclosures, which are filed with a delay and may contain errors or be revised. The Tide Score and other figures are generated algorithmically from public filings and market data and describe historical activity, not a recommendation. Always do your own research and consult a licensed financial advisor before making investment decisions.